Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Cancer"
DOI: 10.1038/bjc.2017.478
Abstract: Background:Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling. The objective of this study was to assess the safety and efficacy of third-line anlotinib for patients with refractory advanced… read more here.
Keywords: advanced non; third line; line; patients refractory ... See more keywords
A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG LU17-21).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.8576
Abstract: 8576 Background: Thymic epithelial tumors (TETs) are rare but the most common tumor of the anterior mediastinum. Platinum-based combination chemotherapy is standard of care which is associated with a 50%-90% overall response rate (ORR) in… read more here.
Keywords: chemotherapy; thymic epithelial; recurrent refractory; study palbociclib ... See more keywords
Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "PLoS ONE"
DOI: 10.1371/journal.pone.0242982
Abstract: Objective To assess the efficacy and toxicity of anlotinib for the treatment of refractory advanced non-small-cell lung cancer (NSCLC). Methods We systematically searched databases for randomized controlled trials on anlotinib treatment for patients with advanced… read more here.
Keywords: advanced non; cell lung; non small; refractory ... See more keywords
Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm, phase-II trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cancer"
DOI: 10.7150/jca.67050
Abstract: This phase-II study (ClinicalTrials.gov identifier: NCT03052478) aimed to evaluate the efficacy and safety of vismodegib, an inhibitor targeting the Hedgehog signaling pathway, in patients with refractory advanced gastric cancer. Patients with refractory advanced gastric cancer,… read more here.
Keywords: safety; patients refractory; advanced gastric; refractory advanced ... See more keywords